Find Academic Supervisors

Dr. Teresa Puthussery is an Associate Professor in the School of Optometry & Vision Science at the University of California, Berkeley. Her research focuses on retinal neurobiology and neurophysiology, investigating how visual signals are encoded in healthy retinas and disrupted during degeneration. She uses advanced techniques like patch-clamp electrophysiology, immunohistochemistry, and microscopy to study retinal circuits, neurotransmitter receptors, and ion channels. Dr. Puthussery teaches courses on vision science anatomy, physiology, and problem-based learning, including VISION SCIENCE 206B/C and 260C. Her research explores questions such as how retinal neurons extract motion/spatial details, how photoreceptor mutations cause degeneration, and how inner retinal circuits adapt post-photoreceptor loss. Recent work includes studies on ON-type direction-selective ganglion cells, optogenetic therapy for vision restoration, and calcium dynamics in foveal ganglion cells post-degeneration. She collaborates on projects involving primate and rodent models, contributing to understanding retinal disease mechanisms and therapeutic targets. Dr. Puthussery’s lab (retinalab.berkeley.edu) emphasizes translational research, bridging basic science and clinical applications. Her work has been published in journals like Nature and Cell Reports , with a focus on retinal degeneration, synaptic plasticity, and optogenetic interventions. She actively participates in training future vision scientists through Berkeley’s Optometry program and oversees GSI affairs as a faculty advisor.

• Retinal Neurobiology
• Neurophysiology
• Retinal Degeneration
• +3 more

Woojin Han is an Assistant Professor in the Departments of Orthopedics and Cell, Developmental & Regenerative Biology at the Icahn School of Medicine at Mount Sinai. His research program focuses on the mechanobiology of skeletal muscle stem and progenitor cells, with applications in disease modeling and the development of advanced therapeutics for muscle injuries and degenerative diseases. Dr. Han earned his BS in Biomedical Engineering from the University of Rochester and his MS and PhD in Bioengineering from the University of Pennsylvania. He completed his postdoctoral training at the Georgia Institute of Technology, where he received awards from the American Federation for Aging Research (AFAR) and the NIH. Dr. Han's research integrates biomaterials, bioengineering, and in vivo genetic approaches to investigate cell-matrix interactions and mechanobiological signaling, aiming to uncover the mechanisms driving muscle regeneration and pathology. His work is supported by the National Institutes of Health (NIH) and the Department of Defense (DoD). Analysis of Dr. Han's recent publications reveals a strong focus on muscle regeneration mechanisms, particularly examining the role of extracellular matrix proteins, mechanical confinement, and signaling pathways in muscle stem cell behavior. His research spans from fundamental mechanobiology to translational applications using biomaterials for tissue regeneration. 2025 NEBEC Emerging Investigator Award 2024 Mount Sinai Faculty Council Award for Junior Faculty 2023 Popular Science's The Brilliant 10 2022 Stephen I. Katz Early Stage Investigator Grant Awardee American Federation for Aging Research (AFAR) award NIH award Dr. Han's research is supported by significant funding from the National Institutes of Health (NIH) and the Department of Defense (DoD). His work bridges basic science and clinical applications, with particular emphasis on developing advanced therapeutics for muscle injuries and degenerative diseases. Through his lab, he mentors junior researchers in the fields of biomechanics, bioengineering, and regenerative medicine. Dr. Han leads the Han Lab, which focuses on skeletal muscle regeneration research. The lab employs a multidisciplinary approach combining biomaterials engineering, molecular biology, and advanced imaging techniques to develop novel strategies for enhancing muscle repair and preventing pathological changes following injury.

• Biomechanics/Bioengineering
• Biomedical Sciences
• Muscle Cells
• +7 more

Michael Dustin is the Kennedy Trust Professor of Molecular Immunology and Director of Research at the Kennedy Institute of Rheumatology , University of Oxford. His career spans leadership roles at Washington University School of Medicine (1993–2000) and Skirball Institute of Biomolecular Medicine at NYU School of Medicine (2001–2013). Education : B.A. in Biology, Boston University (1984) Ph.D. in Cell and Developmental Biology, Harvard University (1990) Prof. Dustin's research focuses on the immunological synapse , a specialized interface between T cells and antigen-presenting cells. His work has revealed supramolecular attack particles as autonomous killing entities, synaptic ectosomes for TCR cargo transfer, and mechanistic insights into T cell signaling pathways. His recent publications highlight advancements in vaccine adjuvant response , T cell receptor dynamics , and glycosphingolipid synthesis in immune cells. Collaborations span neuroscience, cancer immunology, and rheumatology. Scientific Awards : Wellcome Trust Principal Research Fellowship European Research Council Advanced Grant (SYNECT) As Director of the NIH-funded Nanomedicine Center for Mechanobiology (2009–2014), he pioneered mechanobiology applications in immunology. Current projects integrate intravital microscopy and clinical translation for human diseases. His laboratory at Oxford investigates T cell regulation in autoimmune and inflammatory diseases, supported by an international network of collaborators including Wenbiao Gan, Dan Littman, and Dorian McGavern.

• Immunology
• Molecular Immunology
• T-Cell Biology
• +7 more

Jessica A. Mong, PhD , is a Professor in the Department of Pharmacology & Physiology at the University of Maryland School of Medicine , where she also serves as Assistant Dean for Graduate & Post-Doctoral Studies and Director of Graduate Education for the Program in Neuroscience. Her research focuses on the neuroendocrine mechanisms underlying sex differences in sleep circuitry and the estrogenic modulation of sleep-wake cycles. Primary Appointment: Pharmacology & Physiology Administrative Title: Assistant Dean for Graduate & Post-Doctoral Studies Laboratory Director: Program in Neuroscience Research Interests: Dr. Mong's work investigates how ovarian steroids influence sleep-wake behavior through sexually differentiated neuroanatomical substrates. Key areas include: Mechanisms of estrogenic modulation in the median preoptic nucleus (MnPN) Developmental programming of sex differences in sleep sensitivity Translational studies using rodent and nonhuman primate models of menopause Functional significance of hormonal influences on sleep quality and recovery Scientific Trends: Her recent publications (2023-2025) emphasize: Role of KCNMA1 channelopathy in sleep regulation Adenosinergic signaling in MnPN Translational menopause models Estrogen's protective effects against noise-induced hearing loss Sex-dependent responses to kynurenine pathway challenges Awards & Appointments: NIH BIRCWH Scholar (Building Interdisciplinary Research Careers in Women's Health) Co-Chair, Society for Women’s Health Research Interdisciplinary Research Network on Sex-Differences in Sleep Health NIH/NHLBI R01 HL129138 grant recipient Education & Training: B.S., Biology, Gettysburg College (1987-1991) Ph.D., Neuropharmacology, University of Maryland Baltimore (1994-2000) NIH Postdoctoral Fellowship in Endocrinology, Rockefeller University (2000-2003)

• Neuropharmacology
• Neuroendocrinology
• Sleep Research
• +3 more

Prof. Iwan de Esch is a Full Professor in the Department of Chemistry and Pharmaceutical Sciences at VU University Amsterdam, leading the Drug Design & Synthesis division and serving as Head of Department. He holds dual appointments in the Faculty of Science and AIMMS (Amsterdam Institute for Molecular and Life Sciences). His research focuses on understanding molecular interactions for drug discovery, employing CADD and FBDD approaches. He co-founded three biotech companies (De Novo Pharmaceuticals, IOTA Pharmaceuticals, Griffin Discoveries) and coordinates the EU-funded FRAGNET network. PhD from VU University (1998) Postdoc at University of Cambridge (Drug Design Group) Recipient of the 2011 Galenus Research Prize Received grants from EU-FP7, IMI, and Dutch STW Research interests span fragment-based drug design, receptor-ligand interactions, and pre-clinical drug candidate development. His work impacts GPCRs, PDEs, kinases, and protein-protein interactions. He teaches courses on drug discovery methodologies and computational tools. Over 200 peer-reviewed publications and 8 datasets/software contributions highlight his impactful career.

• Drug Design
• Fragment-Based Drug Design (FBDD)
• Computer-Aided Drug Design (CADD)
• +5 more

Bhama Ramkhelawon, PhD, is the Florence and Joseph Ritorto Associate Professor of Surgical Research in the Department of Surgery and Associate Professor in the Department of Cell Biology at NYU Grossman School of Medicine. She is also the Director of Vascular Surgery Scientific Research, leading a dynamic research program focused on vascular biology and disease mechanisms. Her research centers on understanding the molecular and cellular mechanisms underlying vascular aneurysms, peripheral vascular disease, and the interplay between metabolism, inflammation, and aging in the cardiovascular system. Utilizing advanced techniques such as single-cell transcriptomics, mouse models, and clinical data analysis, her lab investigates how immune cells, platelets, and metabolic pathways contribute to vascular pathologies. Recent publications highlight a strong trend in vascular mechanobiology, aging-related transcriptomic changes, adenosine signaling, and inflammatory responses in vascular tissues. Her work bridges basic science with clinical applications, particularly in post-surgical complications like endoleaks and aneurysm repair outcomes. Bhama Ramkhelawon has made significant contributions to the field with over 80 publications in high-impact journals such as Circulation Research , JCI Insight , and Cell Systems . Her research is supported by active clinical trials focusing on vascular aneurysms and peripheral vascular disease, indicating ongoing funding and translational research efforts. She mentors students and researchers as part of her role as a principal investigator and director. Her lab is involved in multi-disciplinary collaborations, integrating cell biology, immunology, and vascular surgery to advance understanding of cardiovascular diseases.

• Vascular Biology
• Cardiovascular Disease
• Inflammation
• +7 more

Professor Samuel Fountain is a leading academic in pharmacology at the University of East Anglia, where he serves as Chair of Pharmacology within the School of Biological Sciences. He holds additional leadership roles as Associate Pro-Vice-Chancellor of the UEA Doctoral College and has previously served as Associate Dean for Postgraduate Research and Director of the Biomedical Research Centre. He is actively supervising multiple PhD students and securing major research funding. BSc (Hons) Pharmacology, University of Leeds (1997–2000) MRC-funded PhD, University of Leeds (2000–2004) Wellcome Trust Research Associate, University of Manchester (2004–2008) BBSRC David Phillips Fellow, University of Leeds (2008–2010) Lecturer to Professor of Pharmacology, University of East Anglia (2010–present) His research focuses on the role of ion channels—particularly P2X receptors—in vascular and adipose tissues, with implications for cardiometabolic diseases. His work integrates pharmacology, physiology, and molecular biology to understand neurovascular and neuroadipose communication, receptor-ligand interactions, and drug discovery. He employs techniques such as pressure myography, patch-clamp electrophysiology, calcium imaging, and molecular modelling. The analysis of his recent publications reveals a strong emphasis on purinergic signalling, ion channel pharmacology, and autonomic control of blood vessels and fat tissue. His work bridges basic science with translational applications, particularly in hypertension, obesity, and metabolic syndrome. Collaborations with AstraZeneca, Merck, and the British Heart Foundation underscore the clinical and pharmaceutical relevance of his research. Notable scientific recognition includes the prestigious BBSRC David Phillips Fellowship. He also contributes to the academic community through editorial roles, including as Editor of Purinergic Signalling , and as a member of the British Pharmacological Society and The Physiological Society. Professor Fountain actively mentors postdoctoral researchers and PhD students, several of whom are funded by BBSRC, BHF, and AstraZeneca iCASE awards. His lab is supported by significant grants from the British Heart Foundation, BBSRC, and industry partners, enabling cutting-edge research in vascular and metabolic pharmacology. He leads multiple active projects on neurovascular transmission, purinergic control, and drug discovery for P2X receptors. His research group operates within the Cells and Tissues research theme at UEA and utilizes advanced experimental platforms including human tissue studies, high-throughput screening, and computational ligand docking. The lab fosters interdisciplinary collaboration between pharmacologists, physiologists, and clinicians, positioning it at the forefront of autonomic and metabolic research.

• Pharmacology
• Ion Channels
• Cardiometabolic Physiology
• +12 more

Nuria Fernández Monsalve is a Professor in the Department of Physiology at the Faculty of Veterinary Medicine, Universidad Autónoma de Madrid. She earned her doctorate from Complutense University of Madrid in 1994 with a thesis on the function of nitric oxide in cerebral circulation regulation. Her research focuses on vascular physiology, particularly examining cerebral and coronary circulation responses to various vasoactive substances. She has extensively studied endothelin-1 effects, ischemia-reperfusion injury, and vascular responses in diabetic and hypertensive conditions. Her work often investigates gender differences in vascular reactivity and the role of nitric oxide and prostanoids in vascular regulation. Analysis of her publication history reveals a consistent research trajectory spanning over two decades, with recent work focusing on the long-term effects of early overnutrition on cardiac function and the role of the renin-angiotensin system. Her studies typically employ animal models including goats, rats, and rabbits to investigate vascular responses under controlled experimental conditions. Dr. Fernández Monsalve's research demonstrates significant contributions to understanding vascular pathophysiology, particularly in the contexts of diabetes, hypertension, and ischemic conditions. Her work has been published consistently in reputable physiology and pharmacology journals, reflecting her standing in the cardiovascular research community.

• Vascular Physiology
• Cerebral Circulation
• Coronary Circulation
• +5 more

Joel D. Trinity, PhD, is an Associate Professor in the Department of Internal Medicine at the University of Utah and holds adjunct appointments in the Department of Nutrition and Integrative Physiology and the Department of Physical Therapy & Athletic Training. He is affiliated with the Geriatrics Division and the Utah Vascular Research Laboratory (UVRL), where he has been a member since 2009. Education: PhD – The University of Texas at Austin MA – The University of Texas at Austin BA – Occidental College BA – University of California, Santa Cruz Postdoctoral Fellowship – University of Utah Advanced Fellowship – George E. Whalen VA Medical Center Research Focus: Dr. Trinity’s laboratory employs integrative in-vivo and in-vitro methodologies to investigate how aging and chronic diseases—particularly hypertension, heart failure, COPD, and peripheral artery disease—impair vascular function and blood-flow regulation. His work emphasizes the triad of neural control, oxidative stress, and endothelial signaling (especially nitric oxide) in determining vascular health across the lifespan. Publications Snapshot: From 2021-2025, Dr. Trinity has published extensively on human cardiovascular responses to exercise, vascular aging, and the vascular consequences of COVID-19. A recurring theme is the translational evaluation of passive leg movement as a non-invasive probe of endothelial function, with studies spanning young adults to older patients with multiple comorbidities. Funding & Collaborations: While specific grant numbers are not provided, the breadth of multi-center collaborations (e.g., RECOVER Consortium for long COVID) and continuous publication output indicate active federal and institutional funding. His laboratory hosts interdisciplinary trainees bridging geriatrics, exercise physiology, and vascular biology. Laboratory & Teams: Dr. Trinity conducts research within the Utah Vascular Research Laboratory (UVRL), leveraging state-of-the-art Doppler ultrasound, plethysmography, and metabolic assays to dissect vascular control mechanisms in human participants and murine models.

• Cardiovascular Physiology
• Exercise and Aging
• Hypertension
• +3 more

Guoqiang Yu is a Professor in the Bradley Department of Electrical and Computer Engineering at Virginia Tech. He holds a joint appointment at the Virginia Tech Research Center - Arlington. His research focuses on integrating machine learning, signal processing, and statistical methods to develop computational tools for analyzing multiplatform biomedical data. Key areas include neuroinformatics, bioinformatics, and systems biology, with applications in understanding human diseases through genomic, proteomic, and imaging data integration. Education: Ph.D. in Electrical Engineering, Virginia Tech (2011) Postdoctoral Fellowship at Stanford University (2012) M.S. Tsinghua University (2004) B.S. Shandong University (2001) Research Interests: Machine learning methodologies for biomedical data analysis, pattern recognition in complex datasets, optimization algorithms for high-dimensional data, stochastic signal processing, and their applications in neurodegenerative diseases (e.g., ALS, Alzheimer's), glial cell biology, and precision medicine. His work emphasizes developing open-source tools like ABDS, CAM3.0, and SynQuant for data normalization, deconvolution, and quantitative imaging analysis. Awards & Service: NSF Career Award (2018) Dean's Award for Excellence in Research (2022) Member of NIH BRAIN Initiative Consortium (2021–present) Associate Editor for BMC Bioinformatics (2017–present) Labs & Teams: Leads the Yu Lab at Virginia Tech, collaborating with multidisciplinary teams in neuroscience, bioengineering, and computational biology. Active in NIH-funded consortia focused on brain data science and large-scale neuroimaging initiatives.

• Machine Learning
• Pattern Recognition
• Optimization
• +9 more

Manu Shankar Hari is a triple-doctorate clinical academic (MB BS MD PhD[immunology] MSc[Epidemiology]) holding specialist fellowships in anaesthesia, intensive-care medicine and epidemiology (FRCA EDIC FFICM). His research fingerprint centres on COVID-19 immunopathology, post-COVID-19 syndromes, sepsis-related platelet biology and T-cell immunosenescence, evidenced by >350 citations and leadership of large UK consortium studies such as PHOSP-COVID and ISARIC4C. Education & Qualifications: MB BS – primary medical degree MD – higher medical doctorate PhD in Immunology MSc in Epidemiology FRCA – Fellowship of the Royal College of Anaesthetists EDIC – European Diploma of Intensive Care Medicine FFICM – Fellowship of the Faculty of Intensive Care Medicine Research Interests: Dr Hari’s work integrates bedside critical care with translational immunology. He interrogates how accelerated immune ageing shapes COVID-19 severity, delineates platelet–immune crosstalk in sepsis, and identifies determinants of recovery from post-COVID-19 dyspnoea using multicentre prospective cohorts and randomised trials. Publication Trends: Recent first-author or senior-author papers in Immunity & Ageing , The Lancet Respiratory Medicine , The Lancet Regional Health – Europe , Shock and JAMA reveal a coherent programme spanning immunosenescence, antiplatelet therapy in COVID-19, and long-COVID respiratory sequelae. Collaborations & Funding: He leads or co-leads national UK consortium grants (PHOSP-COVID, ISARIC4C) involving hundreds of investigators and institutions, supported by NIHR/MRC/UKRI funding streams, with extensive international collaboration networks.

• COVID-19
• Immunology
• Critical Care Medicine
• +5 more

Dr. Stefan Bidula is a Lecturer in Pharmacology at the University of East Anglia's School of Chemistry, Pharmacy and Pharmacology, and a member of the Pathogen Biology Group. His research focuses on antifungal immunity, drug discovery targeting fungal pathogens, and understanding mechanisms of host-microbe interactions. He holds a BSc (Hons) in Genetics and Molecular Biology and a PhD in Biomedical Sciences from the University of East Anglia. Education: BSc (Hons) Genetics and Molecular Biology, University of East Anglia (2008–2011) PhD in Biomedical Sciences, University of East Anglia (2011–2015) Research Interests: Dr. Bidula investigates novel drug targets to combat antifungal resistance, the role of purinergic receptors in immune responses, and the structural biology of nucleic acids (e.g., G-quadruplexes) in pathogenesis. His work integrates biophysics, chemical biology, and bioinformatics to explore mechanisms of fungal detection and inflammation-driven diseases. Grants & Projects: Targeting G-quadruplexes to modulate secondary metabolite production in Aspergillus spp. (2023–2026) Spectroscopic and synthetic facilities for supramolecular and macromolecular systems (2025–2026) Discovery of novel secondary metabolites from marine organisms (2023–2025) Labs & Collaborations: Collaborates on projects involving microbial genomics, cardiovascular biology, and immunology. Part of the Pathogen Biology Group and engaged in interdisciplinary research across pharmacology, microbiology, and structural biology.

• Antifungal Immunity
• Drug Discovery
• Microbial Genomics
• +5 more

Shalini Saggu is an Assistant Professor at the Medical College of Georgia, affiliated with the Department of Neuroscience and Regenerative Medicine. She holds a Ph.D. in Toxicology (2007) and an MS in Toxicology (2003) from Jamia Hamdard, and a BS in Chemistry (2001) from the University of Delhi. Education: Ph.D., Toxicology, Jamia Hamdard (2007) MS, Toxicology, Jamia Hamdard (2003) BS, Chemistry, University of Delhi (2001) Her research focuses on neurotoxicology, Alzheimer's disease mechanisms, and environmental health impacts, particularly exploring how neurotoxicants, hormonal therapies, and plant-derived compounds affect neurodegenerative processes. She has contributed to understanding oxidative stress, neuroinflammation, and synaptic dysfunction in Alzheimer's. Research Themes: Neurotoxicology of environmental pollutants Neuroinflammation in Alzheimer's Plant-based neuroprotective agents Neuropharmacology of adrenergic drugs Mechanisms of memory consolidation She has taught advanced courses in biochemistry and molecular biology, including BCMB 8201: Current Topics & Techniques in Molecular Biology .

• Neuroscience
• Neurotoxicology
• Neurodegenerative Diseases
• +8 more

Paola Lorenzon is an Associate Professor of Physiology at the University of Trieste 's Department of Life Sciences since 2002. She coordinates the International Master's Degree in Neuroscience , serves as Coordinator of the OPBA program , and holds key roles in multiple PhD cycles including Neuroscience and Cognitive Science (XXVIII to XXXVIII cycles) and Biology (SM50). Her research focuses on neuromuscular plasticity , aging effects, and microgravity adaptation mechanisms. Education : Bachelor's in Biological Sciences and PhD in Biochemistry from University of Trieste Research Experience : University of Milan, San Raffaele Milan, University of Ljubljana, University of Bonn Her research spans three main areas: neuromuscular junction plasticity , electrostimulation protocols for muscle regeneration, and Piezo1 ion channels in mechanotransduction. Current projects funded by the Italian Space Agency (MIAG, NEMUSY) investigate muscle atrophy in spaceflight and aging. Notable collaborations include working with Annalisa Bernareggi (electrophysiology), Marina Sciancalepore (electrostimulation), and Alessandra Bosutti (project coordination). Her lab employs primary satellite cell cultures , electrophysiology , and mechanotransduction studies to explore muscle regeneration mechanisms.

• Neuromuscular physiology
• Synaptic plasticity
• Skeletal muscle regeneration
• +6 more

Andrew Bateman, PhD is a Senior Scientist at the Research Institute of the McGill University Health Centre (RI-MUHC) at the Glen site, where he leads research in the Metabolic Disorders and Complications Program within the Centre for Translational Biology. He holds a professorship in the Department of Medicine, Faculty of Medicine and Health Sciences at McGill University, with specific affiliation to the Division of Endocrinology at the McGill University Health Centre. Dr. Bateman's research primarily focuses on progranulin, a protein that plays crucial roles in cell communication, neuroprotection, tissue repair, and cancer progression. His work has demonstrated that progranulin instructs nearby cells to divide and move, inhibits cell death caused by challenges such as starvation or chemotherapeutic drugs, and is essential for keeping nerve cells alive. Notably, his research has shown that losing half of the brain's progranulin levels through mutation causes frontotemporal dementia, a devastating degenerative brain disease. His laboratory also investigates how progranulin is overexpressed in many cancers, rendering cancer cells more aggressive, and how blocking progranulin may serve as a route to cancer therapy. Additionally, his work explores progranulin's role in reducing inflammation and promoting wound repair, including angiogenesis, which has potential applications for people suffering from chronic wounds. Analysis of Dr. Bateman's publication record reveals a consistent focus on progranulin across multiple disciplines including neuroscience, molecular biology, oncology, and vascular biology. His research spans from fundamental protein structure and evolution to clinical applications in neurodegenerative diseases and cancer. A notable trend in his work is the exploration of progranulin's dual role in both neuroprotection and cancer progression, highlighting the complex nature of this regulatory protein. His research has evolved from early work on corticostatic peptides and the immune-hypothalamic-pituitary-adrenal axis to his current specialized focus on progranulin's multifaceted biological functions. Dr. Bateman has made significant contributions to understanding the role of progranulin in various physiological and pathological processes. His work has implications for developing therapeutic approaches for neurodegenerative diseases, cancer treatment, and wound healing. He has established himself as a leading researcher in the field of progranulin biology, with numerous publications in high-impact journals spanning several decades of research.

• Progranulin research
• Neuroprotection
• Tissue repair
• +4 more